BiotechTube

Avexitide

Phase 3Active
1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post Bariatric Hypoglycemia

Conditions

Post Bariatric Hypoglycemia

Trial Timeline

Apr 29, 2025 → Oct 1, 2026

NCT ID
NCT06747468

About Avexitide

Avexitide is a phase 3 stage product being developed by Amylyx Pharmaceuticals for Post Bariatric Hypoglycemia. The current trial status is active. This product is registered under clinical trial identifier NCT06747468. Target conditions include Post Bariatric Hypoglycemia.

What happened to similar drugs?

20 of 20 similar drugs in Post Bariatric Hypoglycemia were approved

Approved (20) Terminated (1) Active (0)
✅raloxifene + PlaceboEli LillyApproved
✅QUTENZAAstellas PharmaApproved
✅Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
✅Teriparatide + Strontium ranelateEli LillyApproved
✅Teriparatide + Zoledronic AcidEli LillyApproved
✅teriparatideEli LillyApproved
✅Teriparatide + RaloxifeneEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06747468Phase 3Active

Competing Products

20 competing products in Post Bariatric Hypoglycemia

See all competitors
ProductCompanyStageHype Score
PRF110- oily solution (Ropivacaine)PainReformPhase 2
25
PRF110PainReformPhase 2
21
ENZ215 + ProliaAlkem LaboratoriesPhase 3
40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
raloxifene + PlaceboEli LillyApproved
43
MBX 1416 (INN imapextide)MBX BiosciencesPhase 2
36
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)MBX BiosciencesPhase 1
23
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
LetrozoleChugai PharmaceuticalPhase 2
35
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
22
LetrozoleChugai PharmaceuticalPhase 2
35
LetrozoleChugai PharmaceuticalPhase 2
35
Placebo + DS-5565Daiichi SankyoPre-clinical
26
YM177 + etodolac + PlaceboAstellas PharmaPhase 3
40
QUTENZAAstellas PharmaApproved
43
QutenzaAstellas PharmaPre-clinical
26
CelecoxibAstellas PharmaPre-clinical
26
ASP8477 + PlaceboAstellas PharmaPhase 2
35